Anti-CD19 antibody preparations

Abstract

To provide stable lyophilized pharmaceutical formulations of an anti CD19 antibody.SOLUTION: A stable lyophilized pharmaceutical formulation comprises an anti-CD19 antibody in a concentration of 20 mg / ml to 125 mg / ml, a buffer, polysorbate in a concentration of 0.005% (w / v) to 0.06% (w / v), and a pH of 6.0. This formulation further comprises a) trehalose in a concentration of 180 mM to 240 mM or b) mannitol in a concentration of 180 mM to 240 mM and sucrose in a concentration of 10 mM to 50 mM.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to stable lyophilized pharmaceutical formulations of anti-CD19 antibodies and provides methods of making and using such formulations. [Background technology]

[0002] B cells are lymphocytes that play a major role in the humoral immune response. B cells are produced in the bone marrow of most mammals and account for 5-15% of the circulating lymphocyte pool. The primary function of B cells is to produce antibodies against various antigens, and they are an essential component of the adaptive immune system.

[0003] Due to the critical role of B cells in regulating the immune system, dysregulation of B cells has been associated with a variety of diseases, including lymphomas and leukemias, including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL).

[0004] The human CD19 molecule is a structurally distinct cell surface receptor expressed on the surface of human B cells, including, but not limited to, pre-B cells, early developmental B cells (i.e., immature B cells), mature B cells that undergo terminal differentiation to become plasma cells, and malignant B cells. CD19 is expressed by most pre-B acute lymphoblastic leukemias (ALL), non-Hodgkin's lymphomas, B-cell chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, hairy cell leukemia, common acute lymphoblastic leukemia, and some null acute lymphoblastic leukemias (Nadler et al., J. Immunol., 131:244-250 (1983); Loken et al., Blood, 70:1316-1324 (1987); Uckun et al., Blood, 71:13-29 (1988); Anderson et al., Blood, 63:1424-1433 (1984); Scheuermann, Leuk. Lymphoma, 18:385-397 (1995)). Expression of CD19 on plasma cells further suggests that it may be expressed on differentiated B-cell tumors, such as multiple myeloma, plasmacytoma, and Waldenstrom's tumor (Grossbard et al., Br. J. Haematol, 102:509-15 (1998); Treon et al., Semin. Oncol, 30:248-52 (2003)).

[0005] Thus, the CD19 antigen is a target for immunotherapy in the treatment of non-Hodgkin's lymphoma (including each subtype described herein), chronic lymphocytic leukemia, and / or acute lymphocytic leukemia.

[0006] MOR208 (previously named XmAb5574) is an Fc-engineered humanized monoclonal antibody that binds to CD19. Increased binding of MOR208 Fc to FcγR due to XmAb-engineered mutations significantly improves in vitro antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and direct cytotoxicity (apoptosis) against tumors compared to the unmodified antibody. MOR208 has not been shown to mediate complement-dependent cytotoxicity.

[0007] MOR208 has been or is currently being studied in clinical trials in CLL, ALL, and NHL. Specifically, a Phase I study entitled "Safety and Tolerability of XmAb® 5574 in Chronic Lymphocytic Leukemia" and a Phase IIa study entitled "Study of an Fc-Optimized Anti-CD19 Antibody (MOR208) for Treating B-Cell Acute Lymphoblastic Leukemia (B-ALL)" have been completed. A Phase IIa study entitled "Study of an Fc-Optimized Anti-CD19 Antibody (MOR208) for Treating Non-Hodgkin's Lymphoma (NHL)" has completed recruitment. Additionally, the following studies are ongoing: a Phase II / III study (B-MIND) entitled "A Study to Evaluate the Efficacy and Safety of MOR208 with Bendamustine (BEN) Versus Rituximab (RTX) with BEN in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)," a Phase II study entitled "A Study to Evaluate the Efficacy and Safety of MOR208 with Idelalisib in Patients with R / R CLL / SLL Pretreated with a BTKi," a Phase II study entitled "A Study to Evaluate the Safety and Efficacy of MOR208 with Lenalidomide in Patients with RR DLBCL," and a Phase II study entitled "Phase II MOR208 in Combination with Lenalidomide for Patients with Relapsed or Refractory CLL, SLL, or PLL, or Elderly Patients with Untreated CLL, SLL, or PLL."

[0008] Therapeutic antibodies and antibody fragments are more complex molecules than traditional organic and inorganic small drug molecules because antibodies are large and have multiple functional groups in addition to complex three-dimensional structures. Therefore, formulating such proteins poses special challenges. For proteins to remain biologically active, formulations must preserve the conformational integrity of at least the core sequence of amino acids in the protein while protecting the protein's multiple functional groups from degradation. Antibody formulations may have a short shelf life, and formulated antibodies may lose biological activity during storage due to chemical and physical instability. The three most common pathways of protein degradation are protein aggregation, deamidation, and oxidation (Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems 10(4):307-377 (1993)). In particular, aggregation can potentially lead to an increased immune response in patients, which raises safety concerns and needs to be minimized or prevented. Summary of the Invention

[0009] It is an object of the present invention to provide formulations of anti-CD19 antibodies, particularly formulations of anti-CD19 antibodies that have a suitable shelf life.

[0010] A suitable formulation for a therapeutic antibody can be an aqueous pharmaceutical composition or a lyophilisate that can be reconstituted to provide a solution for administration to a patient.

[0011] Provided herein is a lyophilized pharmaceutical formulation comprising an antibody. In one embodiment, the formulation comprises an anti-CD19 antibody, a buffer, sucrose, and a surfactant, wherein the formulation has a pH of about 6.0, and the anti-CD19 antibody has the sequence The heavy chain constant domain of TIFF0007824990000001.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000002.tif15170.

[0012] In one aspect, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a buffer, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; or b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0013] In some embodiments, the anti-CD19 antibody comprises an HCDR1 region comprising the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising the sequence MQHLEYPIT (SEQ ID NO: 6).

[0014] In some embodiments, the anti-CD19 antibody comprises an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0015] In some embodiments, the anti-CD19 antibody has the sequence The variable heavy chain of TIFF0007824990000003.tif21170 and the sequence TIFF0007824990000004.tif15170 and the variable light chain.

[0016] In some embodiments, the anti-CD19 antibody has the sequence The heavy chain constant domain of TIFF0007824990000005.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000006.tif14170.

[0017] In some embodiments, the anti-CD19 antibody in the formulation has a concentration of about 20 mg / ml to about 80 mg / ml, hi some embodiments, the anti-CD19 antibody in the formulation has a concentration of about 40 mg / ml.

[0018] In some embodiments, the buffer in the formulation is a citrate buffer or a phosphate buffer.

[0019] In some embodiments, the trehalose in the formulation is about 200 mM. In some embodiments, the trehalose in the formulation is 200 mM.

[0020] In some embodiments, the mannitol in the formulation is about 219 mM and the sucrose in the formulation is about 29 mM. In some embodiments, the mannitol in the formulation is 219 mM and the sucrose in the formulation is 29 mM.

[0021] In some embodiments, the formulation has a pH of about 6.0. In some embodiments, the formulation has a pH of 6.0.

[0022] In some embodiments, the polysorbate in the formulation is polysorbate 20. In some embodiments, the polysorbate (e.g., polysorbate 20) in the formulation is about 0.005% (w / v) to about 0.06% (w / v). In some embodiments, the polysorbate (e.g., polysorbate 20) in the formulation is about 0.02% (w / v). In some embodiments, the polysorbate (e.g., polysorbate 20) in the formulation is 0.02% (w / v).

[0023] In a further aspect, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, citric acid at a concentration of about 25 mM, trehalose at a concentration of about 200 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0.

[0024] In a further aspect, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citric acid at a concentration of 25 mM, trehalose at a concentration of 200 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0.

[0025] In a further aspect, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, citric acid at a concentration of about 25 mM, mannitol at a concentration of about 219 mM, sucrose at a concentration of about 29 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0.

[0026] In a further aspect, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citric acid at a concentration of 25 mM, mannitol at a concentration of 219 mM, sucrose at a concentration of 29 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0.

[0027] In some embodiments, the anti-CD19 antibody in the formulation has not been subjected to prior lyophilization, e.g., is a liquid. In some embodiments, the anti-CD19 antibody in the formulation is a monoclonal antibody. In some embodiments, the anti-CD19 antibody in the formulation is a full-length antibody. In some embodiments, the anti-CD19 antibody in the formulation is an IgG antibody. In some embodiments, the anti-CD19 antibody in the formulation is a humanized or human antibody. In some embodiments, the anti-CD19 antibody in the formulation is an antibody fragment comprising an antigen-binding region. In some embodiments, the antibody fragment is a Fab or F(ab')2 fragment. [Brief explanation of the drawings]

[0028] [Figure 1] FIG. 1 provides the amino acid sequence of MOR208. [Figure 2] Figure 2 shows the number of subvisible particles (SVPs) of MOR208 after 3 months at 40°C. Formulations 3 and 9 were compared, and the mannitol / sucrose formulation produced more particles over time, especially in the 2 μm to 1000 μm range. DETAILED DESCRIPTION OF THE INVENTION

[0029] The term "antibody" refers to monoclonal antibodies of any isotype, including IgG, IgM, IgA, IgD, and IgE. IgG antibodies are composed of two identical heavy chains and two identical light chains, which are linked by disulfide bonds. Each heavy and light chain contains a constant region and a variable region. Each variable region contains three segments called "complementarity-determining regions" ("CDRs") or "hypervariable regions," which are primarily responsible for binding to an antigen epitope. These are designated CDR1, CDR2, and CDR3, numbered sequentially from the N-terminus. The more highly conserved portions of the variable region outside the CDRs are referred to as "framework regions." An "antibody fragment" refers to an Fv, scFv, dsFv, Fab, Fab', or F(ab')2 fragment, or other fragments containing at least one variable heavy chain or variable light chain, each containing CDRs and framework regions.

[0030] "VH" refers to the variable region of the immunoglobulin heavy chain of an antibody or antibody fragment. "VL" refers to the variable region of the immunoglobulin light chain of an antibody or antibody fragment.

[0031] The term "CD19" refers to the protein known as CD19, which has the following synonyms: B4, B lymphocyte antigen CD19, B lymphocyte surface antigen B4, CVID3, differentiation antigen CD19, MGC12802, and T cell surface antigen Leu-12.

[0032] Human CD19 is It has the amino acid sequence TIFF0007824990000007.tif45170.

[0033] "MOR208" is an anti-CD19 antibody. The amino acid sequences of the variable domains are provided in Figure 1. The amino acid sequences of the heavy and light chain Fc regions of MOR208 are provided in Figure 1. "MOR208" and "XmAb 5574" are used synonymously to describe the antibody shown in Figure 1. The MOR208 antibody is described in U.S. Patent Application Publication No. 12 / 377,251, which is incorporated by reference in its entirety.

[0034] Additional antibodies specific for CD19 are described in U.S. Patent No. 7,109,304 (Immunomedics), which is incorporated by reference in its entirety; U.S. Patent Application Publication No. 11 / 917,750 (Medarex), which is incorporated by reference in its entirety; U.S. Patent Application Publication No. 11 / 852,106 (Medimmune), which is incorporated by reference in its entirety; U.S. Patent Application Publication No. 11 / 648,505 (Merck Patent GmbH), which is incorporated by reference in its entirety; U.S. Patent No. 7,968,687 (Seattle Genetics), which is incorporated by reference in its entirety; and U.S. Patent Application Publication No. 12 / 710,442 (Glenmark Pharmaceuticals), which is incorporated by reference in its entirety.

[0035] Additionally, additional antibodies specific for CD19 are available from WO2005012493 (U.S. Patent No. 7,109,304), WO2010053716 (U.S. Patent Application Publication No. 12 / 266,999) (Immunomedics); WO2007002223 (U.S. Patent No. 8,097,703) (Medarex); WO2008022152 (U.S. Patent Application Publication No. 12 / 377,251) and WO2008150494 (Xencor), WO2008031056 (U.S. Patent Application Publication No. 11 / 852,106) (Medimmune); WO2007076950 (U.S. Patent Application Publication No. 11 / 648,505) (Merck Patent GmbH); WO 2009 / 052431 (U.S. Patent Application Publication No. 12 / 253,895) (Seattle Genetics); and WO 2010095031 (12 / 710,442) (Glenmark Pharmaceuticals), WO 2012010562 and WO 2012010561 (International Drug Development), WO 2011147834 (Roche Glycart), and WO 2012 / 156455 (Sanofi), all of which are incorporated by reference in their entireties.

[0036] The term "pharmaceutical formulation" refers to a formulation for administration to a subject. Such a subject may be a human.

[0037] A "stable" formulation is one that can be administered to a patient after storage. In some embodiments, the formulation essentially retains its physical and chemical properties and its biological activity after storage. Various analytical techniques for measuring protein stability are available in the art and are reviewed, for example, in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pub. (1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993).

[0038] Stability can be assessed qualitatively and / or quantitatively in a variety of different ways, including assessing aggregate formation (e.g., by measuring turbidity using size exclusion chromatography and / or by visual inspection), by assessing the biological activity or antigen-binding function of the antibody by ion exchange chromatography (IEC), size exclusion chromatography (HP-SEC), assessing charge heterogeneity using SDS-PAGE analysis and comparing reduced and intact antibody, etc. Instability can include any one or more of aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), clipping / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, unpaired cysteines, N-terminal extensions, C-terminal processing, glycosylation differences, etc.

[0039] As used herein, the "biological activity" of a monoclonal antibody refers to the ability of the antibody to bind to an antigen. This can further include binding of the antibody to an antigen resulting in a measurable biological response that can be measured in vitro or in vivo.

[0040] As used herein, "buffer" refers to a buffer solution that resists pH changes by the action of its acid-base binding components. The buffer solution of the present invention preferably has a pH in the range of about 4.5 to about 7.0, preferably about 5.6 to about 7.0. In one embodiment, the buffer solution has a pH of about 6.0 or 6.0. For example, citrate buffer or phosphate buffer are examples of buffers that adjust the pH within these ranges.

[0041] As used herein, "surfactant" refers to a surface-active agent. The surfactant is preferably a non-ionic surfactant. Examples of surfactants herein include polysorbates (e.g., polysorbate 20 and polysorbate 80); poloxamers (e.g., poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium laurel sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauramidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauramidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyloleyl-taurate; and the MONAQUAT™ series (Mona Industries, Inc., Paterson, NJ); polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g., Pluronic, PF68, etc.). In one embodiment, the surfactant herein is polysorbate 20.

[0042] "Fc region" means the constant region of an antibody, which in humans can be of IgG1, 2, 3, 4 subclass or other. The sequence of the human Fc region is available at IMGT, Human IGH C-REGIONs, http: / / www.imgt.org / IMGTrepertoire / Proteins / protein / human / IGH / IGHC / Hu_IGHCallgenes.html (retrieved May 16, 2011).

[0043] "Administered" or "administration" includes, but is not limited to, delivery in injectable form, such as intravenous, intramuscular, intradermal, or subcutaneous routes, or mucosal routes, such as nasal spray, or by aerosol for inhalation, or as an ingestible solution, capsule, or tablet.

[0044] A "therapeutically effective amount" of a compound or combination refers to an amount sufficient to at least partially halt the clinical symptoms of a given disease or disorder and its complications. The amount effective for a particular therapeutic purpose will depend on the severity of the disease or disorder, as well as the weight and general condition of the subject. It will be understood that determining an appropriate dosage can be accomplished by routine experimentation, constructing a matrix of values, and testing different points within the matrix, all of which is within the ordinary skill of a trained physician or clinical scientist.

[0045] "CDRs" herein are defined by either Chothia et al. or Kabat et al. See Chothia C, Lesk AM. (1987) Canonical structures for the hypervariable region of immunoglobulins. J Mol Biol., 196(4):901-17 (incorporated by reference in its entirety). See Kabat EA, Wu TT, Perry HM, Gottesman KS and Foeller C. (1991). Sequences of Proteins of Immunological Interest. 5th edition, NIH Publication no. 91-3242, US Dept. of Health and Human Services, Washington, DC (incorporated by reference in its entirety).

[0046] "Cross-competition" refers to the ability of an antibody or other binding agent to interfere with the binding of another antibody or binding agent to CD19 in a standard competitive binding assay. The ability or extent to which an antibody or other binding agent can interfere with the binding of another antibody or binding molecule to CD19, and therefore whether it can be said to cross-compete according to the present invention, can be determined using standard competitive binding assays. One suitable assay involves the use of Biacore technology (e.g., by using a BIAcore 3000 instrument (Biacore, Uppsala, Sweden)), which can measure the extent of interaction using surface plasmon resonance technology. Other assays for measuring cross-competition use ELISA-based techniques. A high-throughput process for "epitope-binding" antibodies based on cross-competition is described in International Patent Application WO 2003 / 48731.

[0047] The term "epitope" includes any protein determinant capable of specific binding to an antibody or otherwise interacting with a molecule. Epitope determinants generally consist of chemically active surface groupings of molecules such as amino acids or carbohydrate or sugar side chains and may have specific three-dimensional structural characteristics and specific charge characteristics. Epitopes can be "linear" or "conformational." The term "linear epitope" refers to an epitope in which all of the points of interaction between the protein and an interacting molecule (such as an antibody) occur linearly (continuously) along the primary amino acid sequence of the protein. The term "conformational epitope" refers to an epitope in which discontinuous amino acids combine to form a three-dimensional conformation. In a conformational epitope, the points of interaction occur across a stretch of amino acid residues on the protein that are separated from one another.

[0048] "Binds to the same epitope as" means that the antibody or other binding agent has the ability to bind to CD19 and has the same epitope as the exemplified antibody. The epitopes of the exemplified and other antibodies to CD19 can be determined using standard epitope mapping techniques. Epitope mapping techniques well known in the art include the epitope mapping protocol in Methods of Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes can be determined by simultaneously synthesizing a large number of peptides (peptides corresponding to portions of protein molecules) on a solid support and reacting the peptides with an antibody while they are still bound to the support. Such techniques are known in the art and are described, for example, in U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA 8:3998-4002; Geysen et al. (1985) Proc. Natl. Acad. Sci. USA 82:78-182; Geysen et al. (1986) Mol. Immunol. 23:709-715. Similarly, conformational epitopes are readily identified by determining the spatial conformation of amino acids, for example, by hydrogen / deuterium exchange, X-ray crystallography, and two-dimensional nuclear magnetic resonance. See, for example, the epitope mapping protocol described above. Antigenic regions of proteins can also be identified using standard antigenicity and hydrophobicity plots, such as those calculated using the Omiga version 1.0 software program available from the Oxford Molecular Group. This computer program uses the Hopp / Woods method, Hopp et al. (1981) Proc. Natl. Acad. Sci USA 78:3824-3828, to determine antigenic profiles; and the Kyte-Doolittle technique, Kyte et al. (1982) J. Mol. Biol. 157:105-132, for hydrophobicity plots.

[0049] Embodiment In another embodiment, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a buffer, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0050] In another embodiment, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a citrate buffer or a phosphate buffer, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0051] In some embodiments, the buffer in the formulation has a concentration of 10 to 75 mM. In some embodiments, the buffer in the formulation has a concentration of 20 to 50 mM. In some embodiments, the buffer in the formulation has a concentration of 20 to 40 mM. In some embodiments, the buffer in the formulation has a concentration of 20 to 30 mM. In some embodiments, the buffer in the formulation has a concentration of about 25 mM. In some embodiments, the buffer in the formulation has a concentration of 25 mM. In some embodiments, the buffer in the formulation is a citrate buffer or a phosphate buffer.

[0052] In some embodiments, the citrate buffer in the formulation has a concentration of 10 to 75 mM. In some embodiments, the citrate buffer in the formulation has a concentration of 20 to 50 mM. In some embodiments, the citrate buffer in the formulation has a concentration of 20 to 30 mM. In some embodiments, the citrate buffer in the formulation has a concentration of about 25 mM. In some embodiments, the citrate buffer in the formulation has a concentration of 25 mM.

[0053] In some embodiments, the phosphate buffer in the formulation has a concentration of 10 to 75 mM. In some embodiments, the phosphate buffer in the formulation has a concentration of 20 to 50 mM. In some embodiments, the phosphate buffer in the formulation has a concentration of 20 to 30 mM. In some embodiments, the phosphate buffer in the formulation has a concentration of about 25 mM. In some embodiments, the phosphate buffer in the formulation has a concentration of 25 mM.

[0054] In another embodiment, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a citrate buffer or a phosphate buffer at a concentration of 20 to 50 mM, a polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0055] In another embodiment, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a citrate buffer or a phosphate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0056] In another embodiment, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, citrate buffer at a concentration of about 25 mM, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0057] In another embodiment, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, phosphate buffer at a concentration of about 25 mM, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM Further includes:

[0058] In a further embodiment, the anti-CD19 antibody is a full-length antibody. In a further embodiment, the anti-CD19 antibody is an IgGI, IgG2, IgG3, or IgG4 antibody.

[0059] In another embodiment, the anti-CD19 antibody is a humanized or human antibody. In a further embodiment, the anti-CD19 antibody is an antibody fragment comprising the antigen-binding region. In a further embodiment, the antibody fragment is a Fab or F(ab')2 fragment.

[0060] In another embodiment, the stable lyophilized pharmaceutical formulation is stable at 2-8°C for at least 6 months, at least 12 months, at least 18 months, at least 24 months, or at least 36 months.

[0061] In other embodiments, the stable lyophilized pharmaceutical formulation is stable for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 weeks or more at about 40° C. In certain embodiments, the stable lyophilized pharmaceutical formulation is stable for at least about 1, 2, 3, 4, 5 months or more at about 40° C. In certain embodiments, the stable lyophilized pharmaceutical formulation is stable for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more at about 25° C. In certain embodiments, the stable lyophilized pharmaceutical formulation is stable at about 5° C. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 months or more. In certain embodiments, the stable lyophilized pharmaceutical formulation is stable at about 5+ / -3°C for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 months or more. In certain embodiments, the stable lyophilized pharmaceutical formulation is stable at about −20° C. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 months or more. In certain embodiments, the stable lyophilized pharmaceutical formulation is stable at 5°C or -20°C for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 months or more.

[0062] In further embodiments, the anti-CD19 antibody in the formulation retains at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of its biological activity after storage. In some embodiments, the biological activity is measured by antibody binding to CD19. In some embodiments, the biological activity is measured by antibody binding to CD19 in a FACS CD19 binding assay. In some embodiments, the biological activity is measured by ADCC activity of the anti-CD19 antibody. In some embodiments, the stable lyophilized pharmaceutical formulation is sterile.

[0063] In a further embodiment, the stable lyophilized pharmaceutical formulation is suitable for administration to a subject. In a further embodiment, the stable lyophilized pharmaceutical formulation is suitable for intravenous (IV) or subcutaneous administration.

[0064] In another aspect, provided herein is an article of manufacture comprising a container holding a stable lyophilized pharmaceutical formulation disclosed herein. In embodiments, the container is a glass vial or a metal alloy container. In further embodiments, the metal alloy is 316L stainless steel or Hastelloy.

[0065] In another aspect, provided herein is a method for treating a disease or disorder in a subject, comprising administering to the subject an effective amount of a formulation disclosed herein, wherein the disease or disorder is cancer. In another aspect, provided herein is a use of a stable lyophilized pharmaceutical formulation disclosed herein for treating a disease or disorder in a subject, comprising administering to the subject an effective amount of the formulation, wherein the disease or disorder is cancer. In a further aspect, provided herein is a use of a stable lyophilized pharmaceutical formulation disclosed herein for the manufacture of a medicament for treating a disease or disorder in a subject, comprising administering to the subject an effective amount of the formulation, wherein the disease or disorder is cancer. In one embodiment, the disease or disorder is non-Hodgkin's lymphoma (including each subtype described herein), chronic lymphocytic leukemia, and / or acute lymphocytic leukemia. In embodiments, the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, and mantle cell lymphoma.

[0066] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM wherein the anti-CD19 antibody comprises an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0067] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and sucrose at a concentration of about 10 mM to about 50 mM and the anti-CD19 antibody further comprises the sequence The variable heavy chain of TIFF0007824990000008.tif22170 and the sequence TIFF0007824990000009.tif14170 and the variable light chain.

[0068] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 20 mg / ml to about 125 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 6.0, wherein the formulation further comprises: a) trehalose at a concentration of about 180 mM to about 240 mM; b) Mannitol at a concentration of about 180 mM to about 240 mM and a concentration of about 10 mM to about 50 mM and the anti-CD19 antibody further comprises sucrose of the sequence The heavy chain constant domain of TIFF0007824990000010.tif41170 and the sequence and the light chain constant domain of TIFF0007824990000011.tif15170.

[0069] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation a) trehalose at a concentration of about 200 mM, or b) Mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM wherein the anti-CD19 antibody comprises an HCDR1 region of the sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of the sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of the sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of the sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of the sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of the sequence MQHLEYPIT (SEQ ID NO: 6).

[0070] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation a) trehalose at a concentration of about 200 mM, or b) Mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM and the anti-CD19 antibody further comprises the sequence The variable heavy chain of TIFF0007824990000012.tif21170 and the sequence TIFF0007824990000013.tif15170 and the variable light chain.

[0071] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation a) trehalose at a concentration of about 200 mM, or b) Mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM and the anti-CD19 antibody further comprises the sequence The heavy chain constant domain of TIFF0007824990000014.tif41170 and the sequence and the light chain constant domain of TIFF0007824990000015.tif15170.

[0072] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation a) trehalose at a concentration of about 200 mM, or b) Mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM and the anti-CD19 antibody further comprises the sequence a variable heavy chain having at least 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to TIFF0007824990000016.tif21170; and and a variable light chain having at least 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to TIFF0007824990000017.tif16170.

[0073] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation a) trehalose at a concentration of about 200 mM, or b) Mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM and the anti-CD19 antibody further comprises the sequence a heavy chain constant domain having at least 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to TIFF0007824990000018.tif40170; and and a light chain constant domain having at least 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to TIFF0007824990000019.tif15170.

[0074] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, citrate buffer at a concentration of about 25 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation further comprises trehalose at a concentration of about 200 mM, and wherein the anti-CD19 antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

[0075] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, citrate buffer at a concentration of about 25 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, wherein the formulation further comprises mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM, and the anti-CD19 antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

[0076] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising trehalose at a concentration of about 200 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The variable heavy chain of TIFF0007824990000020.tif21170 and the sequence TIFF0007824990000021.tif16170 and the variable light chain.

[0077] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The variable heavy chain of TIFF0007824990000022.tif23170 and the sequence TIFF0007824990000023.tif15170 and the variable light chain.

[0078] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising trehalose at a concentration of about 200 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000024.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000025.tif15170.

[0079] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a citrate buffer at a concentration of about 25 mM, a polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000026.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000027.tif15170.

[0080] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, a phosphate buffer at a concentration of 20-40 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising trehalose at a concentration of about 200 mM, wherein the anti-CD19 antibody is a compound of the sequence The heavy chain constant domain of TIFF0007824990000028.tif41170 and the sequence and the light chain constant domain of TIFF0007824990000029.tif15170.

[0081] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, phosphate buffer at a concentration of 20-40 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000030.tif41170 and the sequence and the light chain constant domain of TIFF0007824990000031.tif14170.

[0082] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, phosphate buffer at a concentration of about 25 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising trehalose at a concentration of about 200 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000032.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000033.tif15170.

[0083] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of about 40 mg / ml, phosphate buffer at a concentration of about 25 mM, polysorbate at a concentration of about 0.02% (w / v), and a pH of about 6.0, the formulation further comprising mannitol at a concentration of about 219 mM and sucrose at a concentration of about 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000034.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000035.tif15170.

[0084] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citrate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, wherein the formulation further comprises trehalose at a concentration of 200 mM, and wherein the anti-CD19 antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

[0085] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citrate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising mannitol at a concentration of 219 mM and sucrose at a concentration of 29 mM, wherein the anti-CD19 antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6).

[0086] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citrate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising trehalose at a concentration of 200 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: Variable heavy chain and sequence of TIFF0007824990000036.tif21170 Contains the variable light chain of TIFF0007824990000037.tif15170.

[0087] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citrate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising mannitol at a concentration of 219 mM and sucrose at a concentration of 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The variable heavy chain of TIFF0007824990000038.tif21170 and the sequence TIFF0007824990000039.tif15170 and the variable light chain.

[0088] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citrate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising trehalose at a concentration of 200 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000040.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000041.tif16170.

[0089] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, phosphate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising trehalose at a concentration of 200 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000042.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000043.tif14170.

[0090] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, citrate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising mannitol at a concentration of 219 mM and sucrose at a concentration of 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000044.tif41170 and the sequence and the light chain constant domain of TIFF0007824990000045.tif15170.

[0091] In some embodiments, provided herein is a stable lyophilized pharmaceutical formulation, the formulation comprising an anti-CD19 antibody at a concentration of 40 mg / ml, phosphate buffer at a concentration of 25 mM, polysorbate at a concentration of 0.02% (w / v), and a pH of 6.0, the formulation further comprising mannitol at a concentration of 219 mM and sucrose at a concentration of 29 mM, wherein the anti-CD19 antibody is a nucleotide sequence selected from the group consisting of: The heavy chain constant domain of TIFF0007824990000046.tif40170 and the sequence and the light chain constant domain of TIFF0007824990000047.tif15170. [Example]

[0092] Working Example 1: Biophysical characterization of MOR208 The biophysical properties of MOR208 were analyzed for characterization, preformulation screening, and high concentration feasibility.

[0093] To evaluate the structural stability of MOR208, thermal melting experiments were performed using differential scanning fluorimetry (DSF) and CD spectroscopy. MOR208 samples were diluted to a concentration of 1.1 mg / mL. The hydrophobic dye Sypro Orange was added to detect protein denaturation, and melting curves were generated. The samples exhibited a relatively low melting temperature of 47 °C, indicated by a gradual increase in fluorescence.

[0094] MOR208 is a humanized monoclonal antibody that binds to CD19 on B cells and their precursors. The Fc region has been engineered (S239D / I332E) to improve effector function in support of B cell depletion. The currently accepted hypothesis is that this Fc region configuration provides CH2 domain flexibility, which may improve ADCC potency but may also result in a concomitant decrease in the melting temperature of the Fc domain.

[0095] Furthermore, pH screening studies were performed using DSC, RALS, and ITF to identify the most stable pH range of the protein. The pH range from 3.5 to 8.0 was included in this study. Measurements were performed in a mixed buffer system containing the desired pH range. Based on the results obtained, the most stable pH range of MOR208 was identified as pH 6.0 to 7.0.

[0096] Therefore, two buffer systems were identified that provide sufficient buffering capacity in the pH range of 6.0 to 7.0 and are pharmaceutically acceptable for parenteral use. - Citric acid (pH 5.5; 6.0) - Histidine (pH 6.0; 6.5; 7.0)

[0097] Further DSC, RALS, and ITF measurements were performed to examine the thermal stability of MOR208 in 25 mM citrate and 25 mM histidine buffers. Only citrate at a pH of 5.5 exhibited a significantly lower transition temperature, while all other samples tested exhibited comparable thermal stability. This conclusion was also confirmed by RALS and ITF studies.

[0098] Additionally, the effects of ionic strength, sugars, polyols, and polysorbate 20 on the thermal stability of MOR208 were examined. For formulation of samples containing NaCl, sugars, or polysorbate 20, 25 mM citrate buffer at pH 6.0 was selected as the base buffer system. This measurement indicated that the addition of NaCl increased the thermal stability of MOR208, based on a first transition temperature of 52°C. This observation was confirmed by ITF measurements. The results of the RALS study did not identify any effect of NaCl on the thermal stability of MOR208.

[0099] The effects of sugars (trehalose and sucrose) and mannitol on the thermal stability of MOR208 were tested using concentrations of 200 mM trehalose, 210 mM sucrose, and a 180 mM mannitol / 45 mM sucrose mixture. These concentrations were chosen to shift the formulation into the isotonic range. Results from DSC, RALS, and ITF studies indicated that trehalose and sucrose had comparable effects on the thermal stability of MOR208, while the mannitol / sucrose mixture slightly reduced the first transition temperature by approximately 0.8°C.

[0100] The effect of polysorbate 20 on the thermal stability of MOR208 was tested using concentrations of 0.02%, 0.04%, 0.08%, and 0.12%. The results of DSC and RALS measurements showed no significant effect of polysorbate 20 on the thermal stability of MOR208 at the concentrations tested.

[0101] The effect of MgCl on the thermal stability of MOR208 was tested using concentrations of 1, 5, and 10 mM. The results of DSC and RALS measurements showed no significant effect of MgCl on the thermal stability of MOR208 at the concentrations tested.

[0102] Working Example 2: Stability Study of Liquid Formulations of MOR208 Based on the biophysical characterization of MOR208, the following six different liquid formulations were tested in stability studies:

[0103] The following formulations were selected for the stability study: Formulation F1: 10 mM citric acid, pH 6.0 + 0.01% PS 20 + 150 mM NaCl Formulation F2: 25 mM citric acid, pH 6.0 + 0.02% PS 20 + 125 mM NaCl Formulation F3: 25 mM citric acid, pH 6.0 + 0.02% PS 20 + 200 mM trehalose Formulation F4: 25 mM citric acid, pH 6.0 + 0.02% PS 20 + 210 mM sucrose Formulation F5: 25mM histidine, pH 6.0 + 0.02% PS 20 + 140mM NaCl Formulation F6: 25mM histidine, pH 6.0 + 0.02% PS 20 + 230mM trehalose Formulation F7: 25 mM succinate, pH 6.0 + 0.02% PS 20 + 215 mM trehalose Formulation F8: 25mM histidine, pH 6.5 + 0.02% PS 20 + 240mM trehalose

[0104] The protein concentration of all formulations was 20 mg / mL. 10 mL of each formulation was filled into 10 mL vials, closed with coated rubber stoppers, and stored upside down at a controlled temperature of 25°C for 12 weeks. Analytical testing was performed before storage (t0), and after 4, 8, and 12 weeks.

[0105] Formulations 1, 3, 5, and 7 produced fewer subvisible particles over 12 weeks compared to the other formulations. Particles were measured by MFI. Formulation 5 showed the lowest number of SVPs in the >10 μm to >25 μm range.

[0106] The formulations were tested for aggregate and monomer levels by HP SEC. Formulations 2, 3, 7 and 8 showed a higher increase in aggregates over 12 weeks compared to the other formulations.

[0107] The osmolality of Formulation 4 increased after 4 weeks of storage, most likely indicating degradation of the sucrose contained in the formulation.

[0108] The pH shift also indicates degradation of sucrose in formulation 4.

[0109] Further HIC testing showed that formulations 6, 7, and 8 showed a stronger reduction in Peak 3 area % compared to the other formulations, with formulation 8 in particular showing a stronger reduction from 66.1% (initial value) to 52.2% after 12 weeks.

[0110] Physicochemical characterization of MOR208 identified the most stable pH ranges of pH 6.0 and 7.0.

[0111] Citrate, histidine, and succinate buffers were selected as pharmaceutically acceptable buffer systems within the stated pH range. All buffer systems were used at a concentration of 25 mM, which provided sufficient buffering capacity at a protein concentration of 20 mg / mL. The addition of NaCl at a minimum concentration of 125 mM had a weak positive effect on the thermal stability of MOR208 (based on DSC data). The addition of sucrose, trehalose, mannitol / sucrose, and polysorbate 20 did not alter the thermal stability of MOR208.

[0112] Based on the analytical results, the most stable formulations were identified as F1, F3 and F5. Formulation F1: 10 mM citric acid, pH 6.0 + 0.01% PS 20 + 150 mM NaCl Formulation F3: 25 mM citric acid, pH 6.0 + 0.02% PS 20 + 200 mM trehalose Formulation F5: 25mM histidine, pH 6.0 + 0.02% PS 20 + 140mM NaCl

[0113] Samples of these three formulations were further held at 25°C for up to 8 months and tested again. Formulations 1 and 5 provided the greatest stability, but all liquid formulations produced subvisible particles that exceeded pharmacopoeial specifications after 8 months (NMT 6000 particles ≥ 10 μm per vial and NMT 600 particles ≥ 25 μm per vial). Thus, the desired shelf life of at least 24 months at 2-8°C was not achieved by any of the tested liquid formulations with 20 mg / mL protein.

[0114] This fact prompted the decision to initiate the development of a lyophilized dosage form.

[0115] Working Example 3: Freeze-drying feasibility study The lyophilization feasibility study using MOR208 at a concentration of 40 mg / ml included Formulation 3 and new Formulation 9.

[0116] Formulation 3: 25 mM citric acid 200mM Trehalose Dihydrate 0.02% Polysorbate 20 pH 6.0

[0117] Formulation 9: 25 mM citric acid 219mM mannitol 29mM sucrose 0.02% Polysorbate 20 pH 6.0

[0118] Appearance of freeze-dried drug products The appearance of the lyo cakes for both formulations was acceptable. The trehalose-containing formulation was completely amorphous and showed higher shrinkage, but this is merely a cosmetic observation and generally does not correlate with product quality or stability. The mannitol-containing formulation was partially crystalline and provided a higher pharmaceutical quality cake with no shrinkage.

[0119] The quality of the lyophilized MOR208 was tested and compared to the product quality before lyophilization. Table 1 below summarizes the results for Formulations 3 and 9. TIFF0007824990000048.tif226170

[0120] An additional freeze-drying study was conducted that focused solely on subvisible particle (SVP) testing before and after freeze-drying. The results of the study are listed in Table 2 and clearly show that the freeze-drying process did not increase the SVP count. TIFF0007824990000049.tif58170

[0121] Based on the test results, no negative impact of the lyophilization process on product quality was observed. Both formulations provided acceptable cake appearance. Reconstitution time was less than 60 seconds for the formulation containing 40 mg of protein per mL. Reconstitution was achieved by adding 5 mL of water for injection. The moisture level of the mannitol / sucrose formulation was higher compared to the trehalose-containing formulation, which is due to the higher density of the lyophilized cake. The osmolality and protein content (UV scan) decreased after lyophilization, due to the dilution of the product by the reconstitution procedure. The aggregation level did not increase during lyophilization, and few subvisible particles were counted after reconstitution. As a result, both formulations were suitable for lyophilization of MOR208, and the lyophilization feasibility study was completed without issue. Following this study, an accelerated stability study using both formulations was conducted at 40°C over a 3-month period.

[0122] Working Example 4: Accelerated Stability Study After the lyophilization feasibility study was successfully completed, a first stability study was conducted at 40°C (75% rH) for 3 months to compare both formulations. Stability testing included testing for color and visible particles. Additionally, the products were tested by HP-SEC (aggregation), HIC, IEC, binding assay (CD16 Biacore), MFI (subvisible particles), and SDS-Page.

[0123] HP-SEC testing showed a higher increase in aggregates for F9 after 3 months of storage (Table 3). The aggregate level for F3 increased from 0.8% to 1.7%, and the aggregate level for F9 increased from 0.8% to 2.6%. TIFF0007824990000050.tif98170

[0124] The MFI method was used to examine subvisible particles at time t0 and after 4, 8, and 12 weeks. Comparing both formulations, it was clear that the mannitol / sucrose formulation produced more particles over time, especially in the 2 μm to 1000 μm range (Figure 2).

[0125] Based on the analytical results, formulation 3 containing trehalose showed greater stability at 40°C compared to formulation 9. The difference in stability was observed in SVP (MFI) and aggregate levels (HPSEC).

[0126] Conclusion: A lyophilization feasibility study demonstrated that MOR208 could be lyophilized using both formulations and a protein concentration of 40 mg / mL without affecting product quality. Stability conditions were 40°C (75% rH) for a period of 3 months. During this stability study, the trehalose-containing formulation was identified as having increased stability compared to the mannitol / sucrose formulation.

[0127] Working Example 5: Retention Period Allocation For long-term stability studies, MOR208 in Formulation 3 was subjected to real-time storage at 5°C ± 3°C and accelerated storage testing at 25°C ± 2°C.

[0128] The stability studies performed include stability indications and state-of-the-art methods for monitoring drug products with respect to concentration, activity, purity, pharmaceutical and microbiological parameters during storage.

[0129] The following parametric methods are used and are considered the primary stability-indicating tests:

[0130] - Purity by HP-SEC: The stability-indicating properties of HP-SEC were demonstrated by analysis of relevant stress samples, and its ability to detect aggregates was validated by analytical ultracentrifugation.

[0131] - Homogeneity and purity by IEC and reducing / non-reducing CGE: For fragment detection, non-reducing CGE is applied. Chemical modifications resulting in charge variants, such as deamidation, were detected by IEC.

[0132] - Activity assay: Product-specific activity assays, CD19 binding assay (FACS), CD16 binding assay (SPR) and ADCC potency assay showed sensitivity to the relevant stress samples.

[0133] Real-time storage at 5°C ± 3°C and accelerated storage at 25°C ± 3°C are summarized in Tables 4 and 5, respectively. TIFF0007824990000051.tif126170TIFF0007824990000052.tif135170TIFF0007824990000053.tif211170

[0134] Discussion of results: Content and activity The functional activity of MOR208 was monitored using three different activity assays: a CD19 binding assay (FACS), a CD16 binding assay (SPR), and an ADCC-based potency assay. The combination of these three assays encompasses antigen binding, relevant effector binding, and the primary mode of action (ADCC).

[0135] Both binding assays show no clear or relevant trends over time. The ADCC-based potency assay shows some increase over time (both in real time and under accelerated conditions), but the assay also shows higher variability, so the trend is still not considered significant. In summary, all content and activity assays are well within specifications and do not show any significant changes in product quality over the 36-month period.

[0136] purity During 36 months of storage at the intended storage temperature of 5±3°C, none of the purity assays (i.e., HP-SEC, IEC, reduced and non-reduced CGE) show any significant change in product purity. Under accelerated conditions at 25±2°C, HP-SEC shows only one value change at the most recent test time point (a decrease in monomer / increase in fragment value by one increment), which is not reflected in the long-term data and is therefore considered negligible. IEC shows no trend under long-term conditions, but does show a clear trend of a decrease in major peaks / an increase in basic peaks under accelerated conditions.

[0137] In summary, all purity assays are well within specifications and show no significant changes in product quality over a 36 month period.

[0138] Pharmaceutical Testing None of the pharmaceutical tests showed any significant changes over time during 36 months of storage at the intended storage temperature of 5±3° C. In summary, all pharmaceutical tests were well within specifications and showed no significant changes in product quality over the 36 month period.

Claims

1. A liquid formulation comprising an anti-CD19 antibody at a concentration of 20 mg / ml to 125 mg / ml, a citrate buffer at a concentration of 20 to 50 mM, a polysorbate at a concentration of 0.005% (w / v) to 0.06% (w / v), and having a pH of 6.0, wherein the liquid formulation a) trehalose at a concentration of 180 mM to 240 mM, or b) Mannitol at a concentration of 180 mM to 240 mM and sucrose at a concentration of 10 mM to 50 mM and wherein the anti-CD19 antibody further comprises the sequence and a variable heavy chain of the sequence and a variable light chain of sequence and a heavy chain constant domain of the sequence and a light chain constant domain of the antibody.

2. 10. The liquid formulation of claim 1, wherein the anti-CD19 antibody in the liquid formulation is at 40 mg / ml.

3. 3. The liquid formulation according to claim 1 or 2, wherein the citrate buffer in the liquid formulation is at a concentration of 25 mM.

4. 4. The liquid formulation according to claim 1, wherein the trehalose in the liquid formulation is 200 mM.

5. 4. The liquid formulation according to claim 1, wherein the mannitol in the liquid formulation is 219 mM and the sucrose in the liquid formulation is 29 mM.

6. 6. The liquid formulation according to claim 1, wherein the polysorbate in the liquid formulation is polysorbate 20.

7. 7. The liquid formulation according to claim 1, wherein the polysorbate in the liquid formulation is 0.02%.

8. 2. The liquid formulation of claim 1, wherein the anti-CD19 antibody is in an amount of 40 mg / mL, the citrate buffer is at a concentration of 25 mM, the trehalose is at a concentration of 200 mM, polysorbate 20 is at a concentration of 0.02% (w / v), and the liquid formulation has a pH of 6.

0.

9. 2. The liquid formulation of claim 1, wherein the anti-CD19 antibody is in an amount of 40 mg / mL, the citrate buffer is at a concentration of 25 mM, the mannitol is at a concentration of 219 mM, the sucrose is at a concentration of 29 mM, polysorbate 20 is at a concentration of 0.02% (w / v), and the liquid formulation has a pH of 6.

0.

10. 10. The liquid formulation of claim 1, wherein the liquid formulation is for treating a disease or disorder in a subject, the treatment comprising administering to the subject an effective amount of the liquid formulation, and the disease or disorder is non-Hodgkin's lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia.

11. 11. The liquid formulation of claim 10, wherein the disease or disorder is non-Hodgkin's lymphoma.

12. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is diffuse large B-cell lymphoma.

13. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is follicular lymphoma.

14. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is small lymphocytic lymphoma.

15. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue lymphoma.

16. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is marginal zone lymphoma.

17. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma.

18. 12. The liquid formulation of claim 11, wherein the non-Hodgkin's lymphoma is mantle cell lymphoma.

19. 11. The liquid formulation of claim 10, wherein the disease or disorder is chronic lymphocytic leukemia.

20. 11. The liquid formulation of claim 10, wherein the disease or disorder is acute lymphoblastic leukemia.

Images